Current Funding Opportunities

Click here to visit the NCI grant site.

Use your device's search function to find a specific disease or funding source. 



DoD Prostate Cancer Research Program Opportunities

Physician Research Award: This Award supports a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in prostate cancer research. Pre-Application Deadline: August 16, 2018
Early Investigator Research Award : This Award supports prostate cancer-focused research opportunities for individuals in the early stages of their careers, under the guidance of one or more designated Mentors. Pre-Application Deadline: August 16, 2018



DoD Kidney Cancer Research Program Funding Opportunities for 2018

• Idea Development Award – To support new ideas that represent innovative, high-risk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. Letter of Intent Due: September 5, 2018
• Physicians Research Award – To support a mentored research experience to prepare physicians with clinical duties and/or responsibilities for productive careers in kidney cancer research. Letter of Intent Due: September 5, 2018
• Technology Development Award- To support emerging technologies to aid clinical and patient outcomes. Letter of Intent Due: September 5, 2018
• Translational Research Partnership – To support partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications. Letter of Intent Due: September 5, 2018



Biden Cancer Initiative Fierce Awards

The Biden Cancer Initiative is taking nominations for its inaugural FIERCE Awards, recognizing individuals and organizations making a transformative impact on the lives of cancer patients in five categories: prevention and early detection; reducing cancer disparities; patient navigation; survivorship; and LEAP (Leadership through Exemplary and Awesome Purpose).

Nominations Due By: July 31, 2018



Susan G. Komen Career Catalyst Research Grant 

Susan G. Komen is seeking LOIs for outstanding translational research into the understanding, detection, and treatment of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026. 

LOI Due: August 1, 2018


Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low and Middle- Income Countries R21

The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS.

Application Deadline: August 1, 2018



Administrative Supplements to Promote Collaborative Activities in Basic Cancer Research

The purpose of this FOA is to incentivize collaborative, multidisciplinary research across a broad area of challenging topics in basic cancer biology.

Application Deadline: August 6, 2018



HIV/AIDS and the Tumor Niche (R01)

The purpose of this FOA is to advance our understanding of the role of the tumor niche or microenvironment in the risks, development, progression, diagnosis, and treatment of cancer observed in individuals with an underlying HIV infection or AIDS.

Application Deadline: August 7, 2018




Availability of Administrative Supplements for NCI Grant and Cooperative Agreement Awards to Support Pediatric Cancer Control Research Across the Lifespan

This Notice informs current NCI awardees that NCI is interested in Administrative Supplement applications that seek to enhance pediatric cancer control research across the lifespan.

Application Deadline: August 17, 2018

Notice of Availability of Administrative Supplements for Integrative Data Analysis to Extend Research in Cancer Control and Population Sciences

This Notice informs current NCI awardees that NCI is interested in Administrative Supplement applications that seek to integrate/merge or link two or more independent datasets to answer novel cancer prevention and control questions.

Application Deadline: August 17, 2018



Investigation of the Transmission of Kaposi Sarcoma-Associated Herpesvirus (R01/R21)

The purpose of the FOA is to advance our understanding of the modes of transmission of Kaposi sarcoma-associated herpesvirus; the biology of the initial steps of infection; and risk factors for infection in populations living with HIV or at high risk of developing HIV.

Application Deadline: August 18, 2018



NIH Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions-D43

The purpose of this FOA is to encourage applications for research training programs to strengthen the scientific capacity of institutions in low- and middle-income countries (LMICs) to conduct HIV research relevant to the evolving HIV epidemic in their country.

Deadline for Application: August 23, 2018

L earn more about Fogarty HIV>>


Cooperative Human Tissue Network

The purpose of this FOA, issued by the NCI, is to support the Cooperative Human Tissue Network (CHTN). The goal for CHTN is to collect and distribute to investigators high quality human tissue specimens to facilitate basic and early translational cancer research.

Application Deadline: August 28, 2018


NCI Community Oncology Research Program (NCORP) Research Bases

This FOA solicits applications from institutions/organizations to participate as "Research Bases" for the NCI-supported Community Oncology Research Program (NCORP).

Application Deadline: August 31, 2018



NCI Community Oncology Research Program (NCORP) Community Sites

This FOA solicits applications from institutions/organizations to participate as "Community Sites" for the NCI-supported Community Oncology Research Program (NCORP).

Application Deadline: August 31, 2018



NCI Community Oncology Research Program (NCORP) Minority/Underserved Community Sites

This FOA solicits applications from institutions/organizations to participate as "Minority/Underserved Community Sites" for the NCI-supported Community Oncology Research Program (NCORP).

Application Deadline: August 31, 2018



Elsa U. Pardee Foundation Grant

The Elsa U. Pardee Foundation funds research to investigators in United States non-profit institutions proposing research directed toward identifying new treatments or cures for cancer. 

Application Deadline: August 31, 2018



Cancer Prevention, Diagnosis, and Treatment Technologies for Low-Resource Settings (R41/R42 and R43/R44)

This FOA encourages both (R43/R44) Small Business Innovation Research and (R41/R42) Small Business Technology Transfer grant applications from small business concerns to develop or adapt, apply, and validate existing or emerging technologies into user-friendly products for cancer prevention, diagnosis, or treatment in low-resource settings. 

Application Deadline: September 5, 2018

https://grants.nih.gov/grants/guide/pa-files/PAR-18-801.html


Gilead Sciences Research Scholars Program in Hematology/Oncology

Grants of up to $130,000 over two years will be awarded to junior faculty researchers for innovative translational research projects in hematology/oncology (with a focus on hematologic malignancies) that can be either based around a clinical trial with strong correlative science or laboratory investigation.

Application Deadline: September 7, 2018
 


"High" or "Medium" Priority AIDS Research on Non-AIDS-defining or AIDS-defining Cancers (R01/R21)

The purpose of this FOA is to continue advancing our understanding of the risks, development, progression, diagnosis, and treatment of malignancies observed in individuals with an underlying human immunodeficiency (HIV) infection or AIDS. 

Application Deadline: September 7, 2018



HIV and Hepatitis B Co-Infection: Advancing HBV Functional Cure through Clinical Research (R01/R21)

The purpose of this FOA is to fill scientific gaps needed to (a) inform HBV functional cure strategies by furthering our understanding of unique challenges impacting HBV and HIV co-infected hosts and (b) advance the discovery and development of novel HBV interventions that are safe and achieve a functional cure in HIV and HBV co-infected individuals.     

Application Deadline: September 7, 2018



In Vitro and Animal Model Studies on HBV/HIV Co-Infection (R01/R21)

The purpose of this FOA is to stimulate and accelerate development of novel in vitro and small animal models of HBV/HIV co-infection and create a better understanding of the immunopathogenic interactions between HBV and HIV.   

Application Deadline: September 7, 2018



Harnessing Big Data to Halt HIV (R01)

The purpose of this FOA is to promote research that transforms understanding of HIV transmission, the HIV care continuum, and HIV comorbidities using Big Data Science.

Application Deadline: September 7, 2018



Administrative Supplements to Support Cancer Disparity Collaborative Research

The purpose of this trans-NCI FOA is to promote new cancer disparities research among investigators who do not normally conduct it and to encourage the partnership of experienced cancer research investigators with cancer disparities-focused researchers.

Application Deadline: September 10, 2018

DoD Breast Cancer Research Program Funding Opportunities

Applications to the FY18 BCRP are being solicited for the DHA. The BCRP supports innovative, high-impact research focused on ending breast cancer. 

• Breakthrough Award Level 3 & 4: Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. Preproposal Due: September 14, 2018
• Breakthrough Award Level 1 & 2: Supports promising research that has the potential to lead to or make breakthroughs in breast cancer. LOI Due: November 1, 2018



Prostate Cancer Research Program Funding Opportunities 

The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all men experiencing the impact of the disease.

    Health Disparity Research Award – Letter of Intent Due: September 20, 2018
    Health Disparity Scholar Award – Letter of Intent Due: September 20, 2018

http://cdmrp.army.mil/funding/pcrp


Cancer Research Education Grants Program to Promote Diversity - Research Experiences (R25)

The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the nation's biomedical, behavioral, and clinical research workforce.

Application Deadline: September 25, 2018



Cancer Research Education Grants Program to Promote Diversity - Courses for Skills Development (R25)

The over-arching goal of this NCI R25 program is to support educational activities that enhance the diversity of the nation's biomedical, behavioral, and clinical research workforce.

Application Deadline: September 25, 2018



Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01)

This FOA encourages applications that propose to conduct secondary data analysis and integration of existing datasets and database resources, with the ultimate aim to elucidate the genetic architecture of cancer risk and related outcomes.

Application Deadline: October 5, 2018


Rare Diseases Clinical Research Consortia (RDCRC) for Rare Diseases Clinical Research Network (U54 Clinical Trials Optional)

The purpose of this FOA is to invite new and renewal applications for the Rare Diseases Clinical Research Consortia (RDCRC) that comprise the Rare Diseases Clinical Research Network (RDCRN).  The RDCRCs are intended to advance the diagnosis, management, and treatment of rare diseases with a focus on clinical trial readiness.  

Application Deadline: October 9, 2018

 

Administrative Supplements for Research on Dietary Supplements

This FOA announces the availability of administrative supplements to support research in which the supplemental funding would investigate the role of dietary supplements and/or their ingredients in health maintenance and disease prevention. 

Application Deadline: October 15, 2018

 

Administrative Supplements for Validation Studies of Analytical Methods for Dietary Supplement Constituents

This FOA builds on existing NIH awards to support the performance and publication of formal single-laboratory validation studies of quantitative analytical methods.

Application Deadline: October 15, 2018



Electronic Nicotine Delivery Systems (ENDS): Basic Mechanisms of Health Effects (R01/R21)

The purpose of this FOA is to support basic research examining how Electronic Nicotine Delivery Systems (ENDS) aerosols affect normal and disease states relevant to human cells, tissues and organs.

Application Deadline: October 24, 2018


Electronic Nicotine Delivery Systems (ENDS): Population, Clinical and Applied Prevention Research (R01/R21)

The purpose of this FOA is to support studies on electronic nicotine delivery systems (ENDS) that examine population-based, clinical and applied prevention of disease, including etiology of use, epidemiology of use, potential risks, benefits and impacts on other tobacco use behavior among different populations.

Application Deadline: October 24, 2018



Tobacco Use and HIV in Low and Middle Income Countries (R01)

The purpose of this FOA is to encourage research focused on tobacco use and HIV infection in low and middle income countries.

Application Deadline: November 1, 2018



The Role of Epitranscriptomics in Development and Disease 

The purpose of this FOA is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. 

Application Deadline: November 7, 2018

 

Oncology Co-Clinical Imaging Research Resources to Encourage Consensus on Quantitative Imaging Methods and Precision Medicine

The purpose of this FOA is to invite Cooperative Agreement applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials.

Application Deadline: November 19, 2018

Defense Health Program: Department of Defense Ovarian Cancer Research Program - Anticipated Funding Opportunities for Fiscal Year 2018 (FY18)


*Although funds have not been appropriated for the FY18 Department of Defense Ovarian Cancer Research Program (OCRP), the OCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY18 funding opportunities.

This pre-announcement should not be construed as an obligation by the Government, and funding of research projects received in response to these Program Announcements is contingent on the availability of federal funds appropriated for the OCRP. 

As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP). The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, retirees, their family members, and all women impacted by this disease.

Clinical Development Award
• Must be an independent investigator at or above the level of Assistant Professor (or equivalent).
• Supports the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, treatment, or quality of life.
• Near-term impact is expected.
• Preclinical studies in animals are not allowed.
• Small-scale clinical trials (Phase 0, Phase 1, Pilot), studies enriching a clinical trial, and projects related to or associated with ongoing or completed clinical trials are allowed.
• Preliminary data are required.
Optional Nested Early-Career Investigator (ECI): Applications proposing clinical trials and having an ECI that meets the criteria outlined in the Program Announcement/Funding Opportunity will qualify for a higher level of funding.
• Submission of a Letter of Intent is required prior to full application submission.
• Maximum funding of $600,000 for direct costs (plus indirect costs).
• With ECI option the maximum funding is $800,000 for direct costs (plus indirect costs).
• Maximum period of performance is 3 years.

Letter of Intent Due: July 25, 2018

Omics Consortium Development Award
• Must be an independent investigator at the Associate Professor level or above (or equivalent)
• Supports a multi-institutional research effort conducted by leading cancer researchers and advocates that focuses on the origin of ovarian cancer, with an emphasis on risk stratification, screening and early detection.
• Funds support assembling consortium members and laying the groundwork for the research project, including proof of concept.
• Ovarian cancer advocate(s) are required on the research team.
• Funded applicants will be eligible to compete for the consortium award, which will support the execution of the full research project and is anticipated to be offered in FY20, pending availability of funds.
• Submission of a Letter of Intent is required prior to full application submission
• Maximum funding of $400,000 for direct costs (plus indirect costs).
• Period of performance not to exceed 2 years. 

Letter of Intent Due: July 25, 2018


Ovarian Cancer Academy Award – Early-Career Investigator
• Must be within 3 years of his/her last postdoctoral research position (Ph.D.) or clinical fellowship (M.D.), or equivalent as of the full application submission deadline. A letter attesting to eligibility is required.
• Supports the addition of new ECIs to the unique, interactive virtual academy that provides intensive mentoring, national networking, and a peer group for junior faculty.
• ECIs whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.
• A Designated Mentor who is an experienced ovarian cancer researcher with ovarian cancer funding is required.
• A Designated Mentor may only mentor one ECI candidate.
• The Designated Mentor is not required to be at the same institution as the ECI.
• Preliminary data are required.
• Clinical trials are allowed.
• Submission of a Letter of Intent is required prior to full application submission.
• Maximum funding of $725,000 for direct costs (plus indirect costs).
• Maximum period of performance is 4 years. 

Letter of Intent: July 25, 2018 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420.

Applications must be submitted through the Federal Government’s single-entry portal, Grants.gov. Submission deadlines are not available until the Program Announcements are released. For email notification when Program Announcements are released, go to the CDMRP website (http://cdmrp.army.mil) and select Subscribe to Funding Opportunities & Program Communications. For more information about the OCRP or other CDMRP-administered programs, please visit the CDMRP website (http://cdmrp.army.mil).

The Yale Cancer Center Internal Grant Program aims to provide funds for innovative, high quality start-up cancer research programs and provide new investigators with experience and guidance in the grant-writing process. 

The criteria for funding is high quality, innovative cancer research with a likelihood to result in NIH-funded cancer research and encourage collaborations within YCC. Grant competitions will be announced in DirectConnect and will undergo an anonymous NIH-style peer review with written reviews provided to applicants.  


Pew-Stewart Scholars Program for Cancer Research

Yale Cancer Center is pleased to announce the internal competition for the Pew-Stewart Scholars for Cancer Research Program.

The Pew-Stewart Scholars for Cancer Research Program supports assistant professors of outstanding promise in science relevant to the advancement of a cure for cancer.

Deadline for Applications: June 5, 2018



Gabrielle's Angel Foundation for Cancer Research Grants

The Foundation funds cutting-edge research in the fields of leukemia, lymphoma, and related cancers of the blood. Funds support promising scientists who are applying novel and state-of-the-art techniques to address fundamental problems in their genesis and treatment.

Internal Deadline: June 11, 2018



Yale Cancer Innovation Awards

YCC is committed to promoting innovative new approaches to cancer treatment and prevention. In collaboration with an anonymous donor, we are proud to announce an empowering new research award program in cancer research.

YCC is requesting individual or team proposals for projects that have direct relevance to cancer research. We seek projects with the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis, or treatment of cancer. Ultimately, we aim to advance proposals that will solve today’s most challenging problems in cancer research and care.

Application Deadline: June 18, 2018

Learn more about the Yale Innovation award>>


P rogram in Innovative Therapeutics for Connecticut's Health (PITCH) 
 
With a grant from the State of Connecticut’s Bioscience Innovation Fund, this three-year, $10 million-dollar program, provides translational research resources to generate prototype therapeutics that address unmet clinical needs. Contact francine.carland@yale.edu for more information. 
 
Application Deadline: July 15, 2018